8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2005

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-15317	98-0152841
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

14040 Danielson Street

Poway, California 92064-6857

(Address of Principal Executive Offices)(Zip Code)

(858) 746-2400

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Principal Officer Appointment.

On December 22, 2005, ResMed, Inc. (the “Company”) announced that Brett Sandercock has been appointed as the Company’s Chief Financial Officer effective January 1, 2006. Mr. Sandercock, age 38, replaces Adrian Smith who has received the full-time appointment of the Company’s Chief Operating Officer for Europe, a position he has held since November of 2004. Mr. Sandercock joined the Company in 1998 and has held a variety of positions, most recently as Vice President, Treasury and Finance since November 2004. The terms of Mr. Sandercock’s employment agreement as Chief Financial Officer of the Company are not available at this time. The Company will provide this information by filing an amendment to this Form 8-K after the information becomes available.

A copy of the press release relating to the appointment is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibits:	Description of Document
99.1	Press Release dated December 22, 2005

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: December 29, 2005	RESMED INC.
	(registrant)
	By:	/s/ David Pendarvis
	Name:	David Pendarvis
	Its:	Global General Counsel, Senior Vice President Organizational Development and Corporate Secretary

-3-

EXHIBIT INDEX

Exhibits:	Description of Document
99.1	Press Release dated December 22, 2005

-4-

EX-99.1

Exhibit 99.1

ResMed Announces Management Promotions

SAN DIEGO, California, December 22, 2005 – ResMed, Inc, (NYSE: RMD) announced today that, effective January 1, 2006, Adrian Smith will assume full-time responsibility for the management of the Company’s European operations and Brett Sandercock will be appointed Chief Financial Officer. Mr. Smith’s full-time appointment to Chief Operating Officer of Europe is part of an enhanced leadership structure designed to support ResMed’s continued international growth in key markets. Mr. Smith served as ResMed’s Chief Financial Officer since February of 1995 and in November of 2004 assumed the additional responsibility of Chief Operating Officer for Europe. Mr. Sandercock has worked closely with Mr. Smith in ResMed’s finance department since 1998, most recently as Vice President, Treasury and Finance.

“I’m delighted that we have filled these key leadership positions with such qualified and capable internal candidates,” Peter C. Farrell PhD, Chairman and Chief Executive Officer. “Adrian and Brett have significant history and experience with the company and a long-standing working relationship which will ensure a smooth transition into their expanded roles.”

Since February of 1995, Adrian Smith served as ResMed’s Vice President and Chief Financial Officer. From January 1986 through January 1995, Mr. Smith was employed by Price Waterhouse, specializing in the auditing of listed public companies in the medical and scientific field. Mr. Smith holds a B.Ec. from Macquarie University and is a Certified Chartered Accountant.

Brett Sandercock joined ResMed’s finance department in 1998 and most recently served as Vice President, Treasury and Finance. Prior to joining ResMed, Mr. Sandercock held finance and accounting roles at Health Care of Australia and Norton Abrasives. Mr. Sandercock worked at Price Waterhouse from 1989 to 1994, achieving the position of audit manager. Mr. Sandercock holds a B.Ec. from Macquarie University and is a Certified Chartered Accountant.

About ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contact:

Hillary Theakston

Director of Investor Relations

(858) 746-2610

hillaryt@resmed.com